Objectives: Left ventricular thrombus (LVT) is associated with an increased risk of adverse cardiovascular events, and thyroid hormones are known to affect the cardiovascular system in various ways. However, subclinical thyroid dysfunction still deserves to be emphasized, and its impact on the prognosis of patients with LVT is rare but needs to be investigated.
Methods: We used retrospective data from patients diagnosed with LVT at Fuwai Hospital over the past 10 years to assess the relationship between thyroid functional status and prognosis of LVT using multivariate Cox proportional hazards models, and validated the improved predictive effect of including thyroid function in the prognostic assessment of LVT using receiver operating characteristic (ROC) curves.
Results: Subclinical hypothyroidism was significantly associated with a higher incidence of major adverse cardiovascular and cerebrovascular events (MACCEs) (HR 1.774, 95% CI: 1.053-2.989; p = 0.031) and cardiovascular death (HR 1.986, 95%CI: 1.110-3.553; p = 0.021) in LVT patients, whereas no significant correlation was observed in the subclinical hyperthyroidism group. In addition, including thyroid function in the prognostic consideration of LVT patients would contribute to the predictive effect of MACCEs (AUC for 1 year: 0.715; AUC for 2 years: 0.745; AUC for 3 years: 0.684).
Conclusion: Subclinical hypothyroidism can be used as an independent predictor of MACCEs in patients with LVT, and there is a clinical value in using subclinical hypothyroidism as an important factor suggesting a poor prognosis in patients with LVT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/clinem/dgae793 | DOI Listing |
Curr Med Res Opin
March 2025
Merck Healthcare KGaA, Darmstadt, Germany.
Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature.
View Article and Find Full Text PDFThyroid Res
March 2025
Endocrine Unit, Centro Clinico Diagnostico Priamar, Via dei Partigiani 13R, Savona, 17100, Italy.
Background: TSH is the first-line test of thyroid function, and the normal TSH references provided by manufacturers are generally used in diagnoses. In the age of gender medicine, however, there is a need to refine normal TSH ranges.
Aim: The aim of this study was to construct a normal TSH range in women living in our district.
J Endocrinol Invest
March 2025
Gansu University of Chinese Medicine, Lanzhou, 730000, China.
Background: Subclinical hypothyroidism (SCH) is closely associated with heart failure and cardiac hypertrophy, yet the underlying mechanism remains unclear.
Methods: Cardiomyocytes treated with thyroid-stimulating hormone (TSH) were used as an in vitro model. Cardiac-specific TSHR knockout mice (CKO) were treated with isoproterenol (ISO) to induce cardiac hypertrophy in vivo.
FASEB J
March 2025
Clinical Nuclear Medicine Center, Imaging Clinical Medical Center, Institute of Nuclear Medicine, Institute of Clinical Mass Spectrometry Applied Research Center, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Gut microbiota has a close connection to different thyroid disorders, yet research on its links to subclinical hypothyroidism (SCH) remains limited and insufficient. In this study, we explored the potential relationship between the gut microbiota and SCH, as well as dyslipidemia in SCH mice. The SCH mouse model was induced using methimazole.
View Article and Find Full Text PDFLipids Health Dis
March 2025
Department of Geriatric Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, China.
Subclinical hypothyroidism (SCH) contributes to obesity, with the liver acting as a crucial metabolic regulator. Thyroid-stimulating hormone (TSH) affects systemic lipid balance, potentially linking SCH to obesity. While the direct impact of TSH on hepatic lipid metabolism has been extensively documented, its role in modulating lipid dynamics in peripheral organs through liver-mediated pathways remains insufficiently understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!